Current Cancer Vaccine and Immunotherapy Trials
Current Trials: Breast Cancer
A Phase II Trial of the Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes from Five Antigens Associated with Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Patients with Triple Negative Breast Cancer
Study Stage
Phase II
Stage of Disease
I, II or III
Tumor Type
Triple Negative Breast Cancer (TNBC)
Study Treatment
Vaccine
Study Population
A Phase II Trial of the Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes from Five Antigens Associated with Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Patients with Triple Negative Breast Cancer+C17
Results Summary
A Phase II Study of Concurrent WOKVAC Vaccination with Neoadjuvant Chemotherapy and HER2-Targeted Monoclonal Antibody Therapy
Study Stage
Phase II
Stage of Disease
I, II, III
Tumor Type
Breast
Study Treatment
Vaccine + chemo+HER2-targeted monoclonal antibody
Study Population
Patients with HER2+ breast cancer, regardless of hormone receptor status, who are planning to receive neoadjuvant cytotoxic chemotherapy and HER2-targeted monoclonal antibody therapy prior to planned surgery.
Results Summary
A Phase I Dose Escalation Trial of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients with Treatment Refractory HER2+ Metastatic Breast Cancer
Study Stage
Phase I
Stage of Disease
IV
Tumor Type
Breast
Study Treatment
Vitamin E derivative + HER2 targeted monoclonal antibody
Study Population
Stage IV HER2+ breast cancer who have been treated with definitive therapy and received maintenance HER2-targeted monoclonal antibody therapy; and currently have measurable disease not considered curable by conventional therapies.
Results Summary
Current Trials: Ovarian Cancer
A Phase II Study of Anti-PD-1 in Combination with Carboplatin to Prevent Progression after Serologic Detection of Recurrent Ovarian Cancer
Study Stage
Phase II
Stage of Disease
III, IV
Tumor Type
Ovarian, fallopian tube, peritoneal
Study Treatment
Chemo + Anti-PD-1 therapy
Study Population
Ovarian, fallopian tube, primary peritoneal cancer in complete remission undergoing cancer surveillance found to have CA-125 elevation, but no radiographic evidence of recurrence.
Results Summary
Current Trials: Non-Small Cell Lung Cancer
A Phase II Randomized Study of Safety and Efficacy of a Multiple Antigen Vaccine (STEMVAC) in Non-Small-Cell Lung Cancer (NSCLC) Patients
Study Stage
Phase II
Stage of Disease
IV
Tumor Type
Non-small cell lung cancer (NSCLC)
Study Treatment
Vaccine
Study Population
Patients with histologically-confirmed diagnosis of stage IV NSCLC, who are not eligible for approved targeted therapies, have completed 3 - 4 cycles of chemoimmunotherapy (induction treatment), have achieved responsive or stable measurable disease and are receiving or are candidates to continue maintenance treatment with pembrolizumab +/- pemetrexed
Results Summary
Current Trials: Other/Multiple Cancers
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)
Study Stage
Phase II
Stage of Disease
IV
Tumor Type
bladder, biliary tract, cervical, endometrial, ovarian, pancreatic, other rare tumors
Study Treatment
Trastuzumab Deruxtecan (T-DXd)
Study Population
Patients with stage IV HER2 expressing disease who have progressed following at least one prior systemic treatment for metastatic or advanced disease. A total of 15 eligible patients will be enrolled
Results Summary
Past Cancer Vaccine and Immunotherapy Trials
Phase I/II Study of Adoptive T Cell Therapy Following in vivo Priming with a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine in Patients with Advanced Stage HER2 Overexpressing Breast Cancer
Study Stage
Phase I/II
Stage of Disease
IV
Tumor Type
Breast
Study Treatment
Vaccine + Autologous T cells
Study Population
Patients with HER2+ Stage IV breast cancer who have been maximally treated and have not achieved a complete remission.Â
Study Results
Anti-PD-1 Therapy in Combination with Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Study Stage
Phase I/II
Stage of Disease
Platinum resistant ovarian, fallopian tube and primary peritoneal cancer
Tumor Type
Ovarian, fallopian tube and primary peritoneal
Study Treatment
Pembrolizumab + platinum chemotherapy
Study Population
Subjects who had an initial response to platinum-based (cisplatin or carboplatin) chemotherapy and who have progressed within 6 months of completing platinum-based chemotherapy and have subsequently received at least one non-platinum therapy regimen will be eligible to enroll.
Study Results
A Phase ll Study of Concurrent IGFBP-2 Vaccination and Neoadjuvant Chemotherapy to Increase the Rate of Pathologic Complete Response at the Time of Cytoreductive Surgery
Study Stage
Phase II
Stage of Disease
III/IV
Tumor Type
Ovarian, fallopian tube, peritoneal
Study Treatment
Vaccine + Neoadjuvant Chemotherapy
Study Population
Newly diagnosed patients with ovarian/fallopian tube/peritoneal cancer recommended for neoadjuvant chemotherapy with carboplatin and paclitaxel with subsequent cytoreductive surgery due to extent of metastases.
Study Results
Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSK®) Concurrently with a HER2 ICD Peptide-Based Vaccine in Patients with Stage IV Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Study Stage
Phase I/II
Stage of Disease
IV
Tumor Type
HER2+ Breast Cancer
Study Treatment
Vaccine +Polysaccharide Krestin + trastuzumab/pertuzumab
Study Population
Patients with Stage IV HER2+ breast cancer who have been treated with definitive therapy and are receiving maintenance HER2-targeted monoclonal antibody therapy (defined as trastuzumab monotherapy or combination trastuzumab and pertuzumab therapy); and are currently without evidence of disease (NED) or have stable-bone only disease.Â
Study Results
Phase II Study of a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Patients with Locally Advanced or Stage IV HER2 Positive Breast Cancer
Study Stage
Phase II
Stage of Disease
IIIB, IIC, IV
Tumor Type
HER2+ Breast Cancer
Study Treatment
Vaccine
Study Population
Patients with stage IIIB, IIIC or IV HER2+ Breast Cancer who have initiated treatment within the past year; and are currently without evidence of disease (NED) or have stable-bone only disease.
Study Results
Phase I/II Study of Combination Immunotherapy for the Generation of HER-2/neu (HER2) Specific Cytotoxic T Cells (CTL) in vivo
Study Stage
Phase I/II
Stage of Disease
IV
Tumor Type
Breast, ovarian
Study Treatment
Vaccine + trastuzumab
Study Population
Patients with HER2 overexpressing Stage IV breast cancer who are on maintenance trastuzumab alone after being treated with chemotherapy and trastuzumab until there is no evidence of disease (NED) or stable disease. Stage IV HER2 overexpressing ovarian cancer patients who are on maintenance trastuzumab alone or after being treated with chemotherapy and trastuzumab until there is no evidence of disease (NED) or stable disease.
Study Results
Phase I Dose Escalation Study of Intraperitoneal (I.P.) ONTAK Administered to Patients with Advanced Stage Ovarian Cancer
Study Stage
Phase I
Stage of Disease
III/IV
Tumor Type
Epithelial ovarian carcinoma, Primary peritoneal carcinoma, or Epithelial fallopian tube carcinoma
Study Treatment
ONTAK administered intraperitoneally
Study Population
Patients with advanced stage refractory ovarian carcinoma who are unable to achieve first complete remission (CR) with first or second line chemotherapy or who have disease relapse after achieving second CR
Study Results
A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients with Advanced Ovarian Cancer (OC)
Study Stage
Phase I
Stage of Disease
III, IV
Tumor Type
Ovarian
Study Treatment
IGFBP-2 Vaccine
Study Population
Patients with stage III or IV ovarian cancer, who have been treated to complete remission with standard therapies including primary debulking surgery
A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Derived From Three Breast Cancer Antigens (IGFBP-2, HER2, and IGF-1R) in Patients with Breast Cancer
Study Stage
Phase I
Stage of Disease
I, II, III
Tumor Type
Breast
Study Treatment
WOKVAC Vaccine
Study Population
Patients with non-metastatic, node positive, HER2 negative breast cancer, who are in remission and defined as having no evidence of disease (NED)
Study Results
A Phase I Safety and Efficacy Trial of a DNA Plasmid Based Vaccine Encoding the HER-2/neu (HER2) Intracellular Domain in Subjects with HER-2/neu-Overexpressing Tumors
Study Stage
Phase I
Stage of Disease
III, IV
Tumor Type
Breast and Ovarian
Study Treatment
HER2 Vaccine
Study Population
Stage III or Stage IV breast cancer in remission and defined as "no evidence of disease.
Stage III or IV ovarian cancer. All subjects must be in first complete remission with a normal and stable CA125. Two sequential normal CA 125 values must be documented, the most recent within thirty days of enrollment in study.
Study Results
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive (HER2+) Breast Cancer
Study Stage
Phase II
Stage of Disease
I, II, III
Tumor Type
Breast
Study Treatment
Vaccine
Study Population
HER2+ Stage I to III breast cancer who had residual disease at time of surgery
Study Results
A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients
Study Stage
Phase I
Stage of Disease
III, IV
Tumor Type
Breast
Study Treatment
Vaccine
Study Population
HER2- breast cancer that has been treated. Now with no evidence of disease (NED) or stable bone only disease after primary or salvage therapy will be eligible for this study.
Study Results
Do you think you might be eligible for one of our cancer vaccine trials?
​For more information regarding CVI cancer vaccine and immunotherapy trials, please call our Patient Coordinator at 866-932-8588, or send an email to cvitrial@uw.edu. We strive to get in touch within 48 hours of receiving your inquiry.
Clinicians interested in receiving regular updates on open clinical trials may send a request to be added to our mailing list to kkd@uw.edu.
WHAT'S NEW AT THE CVI
